Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rossari Biotech Ltd ( (IN:ROSSARI) ) has shared an announcement.
Rossari Biotech reported its highest-ever quarterly performance in Q4 FY26, with consolidated revenue from operations rising 18% year-on-year to Rs 684.9 crore and EBITDA increasing 11% to Rs 77.3 crore, although the EBITDA margin softened slightly to 11.3%. Net profit for the quarter jumped 34% to Rs 46 crore, reflecting improved profitability and operating leverage despite some margin moderation.
For the full year FY26, the company delivered 15% growth in consolidated revenue to Rs 2,396.4 crore and an 8% rise in EBITDA to Rs 286 crore, with the EBITDA margin at 11.9% compared with 12.7% in the previous year. Full-year profit after tax increased 9% to Rs 149.2 crore and diluted EPS improved to Rs 26.93, underscoring steady earnings expansion and reinforcing Rossari Biotech’s positioning as a growing player in the specialty chemicals space.
More about Rossari Biotech Ltd
Rossari Biotech Limited is a specialty chemicals manufacturer that provides intelligent and sustainable solutions to customers across industries. Headquartered in Mumbai, the company focuses on value-added chemical formulations, serving diverse end-markets where performance, efficiency, and environmental considerations are key purchase drivers.
Average Trading Volume: 4,540
Technical Sentiment Signal: Sell
Current Market Cap: 28.59B INR
For an in-depth examination of ROSSARI stock, go to TipRanks’ Overview page.